Category: Investment, Biotech, Biodefense
Medical Technology Breaking News: Aethlon Medical, Inc. (OTCQB: AEMD) - "The Identification of Neurological Disorders in NFL Players"
Visit this company: www.aethlonmedical.com
New York, NY - September 16, 2014 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD) today published a new blog post on The Chairman’s Blog, written by the Company’s Chairman and Chief Executive Officer, James A Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
In his new blog, Mr. Joyce expands on the Exosome Sciences blood-based "liquid biopsy" to potentially identify and monitor CTE in a living person. Mr. Joyce reflects on the impact this diagnostic can have on the future of advancing candidate therapies to treat CTE and what this can mean for Aethlon Medical and its subsidiary Exosome Sciences. Read the full blog post from Mr. Joyce on TheChairmansBlog.com.
About Aethlon Medical
Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease and cancer. The company's lead product is the Aethlon Hemopurifier(R), a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. Additional information can be found online at http://www.aethlonmedical.com/.
TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com
SOURCE: The Chairmans Blog
James A. Joyce
Chairman and CEO
Chief Financial Officer
Get free news alerts: Sign up here
Disclaimer/ Disclosure: Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: Disclosure: AEMD subscribes to the Investorideas newswire content publishing annual program (9700 per Year, paid quarterly) for news publishing.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.